https://doi.org/10.5812/hepatmon.66419

WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens

authors:

avatar Jamshid Vafaeimanesh ORCID 1 , 2 , avatar Fahimeh Safarnezhad Tameshkel ORCID 1 , avatar Hossein Ajdarkosh 1 , avatar Azita Azarkeyvani 3 , avatar Mahmoodreza Khoonsari 1 , avatar Amirhossein Faraji 1 , avatar Masoudreza Sohrabi 1 , avatar Sima Aten 1 , avatar Hossein Keyvani ORCID 1 , avatar Farhad Zamani 1 , *

Gastrointestinal and Liver Disease Research Center, Iran University of Medical Sciences, Tehran, IR Iran
Gastroenterology and Hepatology Disease Research Center, Qom University of Medical Sciences, Qom, IR Iran
Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Department of Thalassemia Clinic, Tehran, IR Iran
Hepatitis Monthly: Vol.18, issue 9; e66419
published online: July 11, 2018
article type: Research Article
received: January 17, 2018
revised: June 5, 2018
accepted: June 9, 2018

How To Cite Vafaeimanesh J, Safarnezhad Tameshkel F, Ajdarkosh H, Azarkeyvani A, Khoonsari M, et al. WITHDRAWN: Efficacy and Side Effects of Sofosbuvir and Daclatasvir for Treatment of Hepatitis C in Thalassemia Major Patients with Treatment Experience of Interferon-Based Regimens. Hepat Mon. 2018;18(9):e66419. https://doi.org/10.5812/hepatmon.66419.

Withdrawal Note

This article is withdrawn by EIC - on behalf of the editorial board- because of the case that it was published simultaneously in another journal (https://www.ncbi.nlm.nih.gov/pubmed/30084415). After the investigation raised by EIC, authors confessed to their mistake in double submission (#346818) and due to the status of the article (In Press) and journal policy about withdrawal regulations (http://hepatmon.com/en/knowledgebase/category/tree.html#withdrawal_regulations.html), we decided to withdraw it from our journal.